Experimental design and optimization of a novel dual-release drug delivery system with therapeutic potential against infection with Helicobacter pylori

Arrúa, Eva Carolina; Sánchez, Sofía V.; Trincado, Valeria; Hidalgo, Antonio Vásquez; Quest, Andrew F. G.; Morales, Javier

doi:10.1016/j.colsurfb.2022.112403

Cited by 3 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other approaches have focused not on the therapeutic compounds prescribed, but on creating drug delivery systems (DDSs) suitable for the optimal administration of target APIs. This is the case of the lipid nanocarriers designed for the encapsulation of clarithromycin, which later were incorporated into microcapsules, in a study published in February 2022 [ 68 ]. Effective antibiotic release from this gastroretentive and pH-sensitive DDS was achieved, thus offering an alternative to optimize anti- H. pylori treatments.…”

Section: Solution Ii: Development Of Smart Gastroretentive Ddssmentioning

confidence: 99%

Scope and Limitations of Current Antibiotic Therapies against Helicobacter pylori: Reviewing Amoxicillin Gastroretentive Formulations

Grosso

de-Paz

2022

Pharmaceutics

View full text Add to dashboard Cite

Even though general improvement of quality of life has happened around the globe, statistics show that gastric cancer is still a very serious medical concern in some regions of the world. A big portion of malignant neoplasms that develop inside the stomach are linked to an infection of Helicobacter pylori; in fact, this pathogen has already been categorized as a group 1 carcinogen by the World Health Organization (WHO). Still, the efficacy of current anti-H. pylori therapeutic approaches is insufficient and follows a worrying decreasing trend, mainly due to an exponential increase in resistance to key antibiotics. This work analyzes the clinical and biological characteristics of this pathogen, especially its link to gastric cancer, and provides a comprehensive review of current formulation trends for H. pylori eradication. Research effort has focused both on the discovery of new combinations of chemicals that function as optimized antibiotic regimens, and on the preparation of gastroretentive drug delivery systems (GRDDSs) to improve overall pharmacokinetics. Regarding the last topic, this review aims to summarize the latest trend in amoxicillin-loaded GRDDS, since this is the antibiotic that has shown the least bacterial resistance worldwide. It is expected that the current work could provide some insight into the importance of innovative options to combat this microorganism. Therefore, this review can inspire new research strategies in the development of efficient formulations for the treatment of this infection and the consequent prevention of gastric cancer.

show abstract

Section: Solution Ii: Development Of Smart Gastroretentive Ddssmentioning

confidence: 99%